The magic of small structure differences in a sodium-glucose cotransporter drug discovery project-14 C-labelled drug candidates in a key-differentiating study
- J Labelled Comp Radiopharm. 2021 Feb;64(2):73-76. doi: 10.1002/jlcr.3869.
- 1. Research and Development, DMPK, Sanofi-Aventis Germany Deutschland GmbH, Frankfurt, Germany.
- 2. Research and Development, Integrated Drug Discovery, Sanofi-Aventis Germany GmbH, Frankfurt, Germany.
We describe the dramatic differences in the synthesis and physiological and pharmacokinetical profiling of two sodium-glucose cotransporter (SGLT) drug candidates AVE2268 and AVE8887 with very similar chemical structures. It is a classic example of how a radioactive study was able to spare resources in preclinical development prior to entering a costly clinical program. It also demonstrated that radioactive compounds can be used to study differences between two very similar compounds in vivo.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: SGLTResearch Areas: Metabolic Disease